Focus Investment Banking

AUGUST 6, 2023

ESG isn’t just a matter for large, publicly traded companies. This is particularly true if your partners are publicly traded or foreign-owned. It’s increasingly becoming a must for small and medium-sized businesses. Strength in ESG helps reduce companies’ risk of adverse government action,” adds McKinsey.

Middle Market 52

Middle Market Business Government Profitability 52

The TRADE

JULY 11, 2023

” The review consists of seven recommendations including the introduction of a Research Platform, which will provide a central facility for the promotion, sourcing and dissemination of research on publicly traded companies – potentially open to all, but in particular, for smaller cap companies.

Asset Management 40

Asset Management Investment Government Capital Market 40

Cooley M&A

JANUARY 25, 2023

Will 2023 see a resurgence of traditional public M&A deals or will macro factors and the looming threat of regulatory review continue to push biotechnology companies down creative paths? It’s a more challenging market environment right now than we’ve seen in many years,” said Charlie Kim , who co-chairs Cooley’s capital markets practice.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Collaboration 40

Cooley M&A

JANUARY 22, 2020

If, however, capital markets and the economy weaken in 2020, M&A transactions may be the only viable option for life sciences companies to access capital, in which case we would expect to see more M&A transactions by number, but they would likely be paired with lower purchase prices and/or more highly structured.

M&A 40

M&A Pharmaceutical Acquisitions Capital 40

Cooley M&A

OCTOBER 29, 2020

On September 24, Cooley M&A partner, Garth Osterman, moderated a webinar on the current trend in going public: SPACs! For example, SPAC sponsors may be subject to shorter lock-up periods if certain pricing triggers are met, or the target shareholders may be subject to a longer lock-up period to align with that of the SPAC sponsors.

M&A 52

M&A IPO Valuation Mergers and Acquisitions 52

Cooley M&A

JANUARY 22, 2021

But given the number of SPACs that went public in 2020 and have yet to announce a business combination (204 of 247), expect to see many more SPAC business combinations in 2021. Apologies in advance to our capital markets colleagues – it looks like we’re not done with you just yet!). A Different Prescription for Poison Pills.

M&A 40

M&A IPO Mergers and Acquisitions Business 40

Cooley M&A

JANUARY 20, 2022

19 treatments from Pfizer, Merck and potentially others hitting the market soon , we expect Big Pharma to continue to parlay this cash flow into growth in other areas of strategic focus. The strong capital markets environment that has prevailed during the past few years has enabled a large number of development-stage and one?product,

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Mergers 40

Cooley M&A

JANUARY 25, 2023

Convergence of tech and healthcare drives digital health deals As discussed in our 2022 Life Sciences M&A Year in Review blog post , decreased valuations and challenging capital markets also impacted healthcare companies last year, and digital health companies – health companies that build and sell technology – were no exception.

M&A 52

M&A Mergers and Acquisitions Private Equity Mergers 52